A Phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma and other solid tumor
31
ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
First Line
Advanced curatively unresectable solid tumors failing standard therapy.
HCC: must have failed at least 1 line of standard therapy
Gastric cancer: must have failed at least 2 line of standard therapy (inclusive of adjuvant treatment)
Other solid tumours: must have failed at least 1 line of standard therapy
Subscribe to our mailing list to get the updates to your email inbox...